Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S.

J Clin Invest. 2010 Dec;120(12):4466-77. doi: 10.1172/JCI41717. Epub 2010 Nov 22.

2.

Hepcidin and Hfe in iron overload in beta-thalassemia.

Gardenghi S, Ramos P, Follenzi A, Rao N, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S.

Ann N Y Acad Sci. 2010 Aug;1202:221-5. doi: 10.1111/j.1749-6632.2010.05595.x. Review.

3.

Liver expression of hepcidin and other iron genes in two mouse models of beta-thalassemia.

De Franceschi L, Daraio F, Filippini A, Carturan S, Muchitsch EM, Roetto A, Camaschella C.

Haematologica. 2006 Oct;91(10):1336-42.

4.

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.

Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD.

Blood. 2013 Feb 14;121(7):1200-8. doi: 10.1182/blood-2012-09-453977. Epub 2012 Dec 6.

5.

Exogenous iron increases hemoglobin in beta-thalassemic mice.

Ginzburg YZ, Rybicki AC, Suzuka SM, Hall CB, Breuer W, Cabantchik ZI, Bouhassira EE, Fabry ME, Nagel RL.

Exp Hematol. 2009 Feb;37(2):172-83. doi: 10.1016/j.exphem.2008.10.004. Epub 2008 Dec 6.

PMID:
19059700
6.

A tincture of hepcidin cures all: the potential for hepcidin therapeutics.

Bartnikas TB, Fleming MD.

J Clin Invest. 2010 Dec;120(12):4187-90. doi: 10.1172/JCI45043. Epub 2010 Nov 22.

7.

Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.

Hendy OM, Allam M, Allam A, Attia MH, El Taher S, Eldin MM, Ali A.

Egypt J Immunol. 2010;17(2):33-44.

PMID:
23082485
8.

Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E.

Haematologica. 2007 May;92(5):583-8.

9.

mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.

Weizer-Stern O, Adamsky K, Amariglio N, Rachmilewitz E, Breda L, Rivella S, Rechavi G.

Am J Hematol. 2006 Jul;81(7):479-83.

10.

Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.

Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S.

Blood. 2007 Jun 1;109(11):5027-35. Epub 2007 Feb 13.

11.

[Thalassemia: therapeutic hopes carried by hepcidin].

Vaulont S, Labie D.

Med Sci (Paris). 2011 May;27(5):473-5. doi: 10.1051/medsci/2011275009. Epub 2011 May 25. French. No abstract available.

12.

Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Kautz L, Jung G, Du X, Gabayan V, Chapman J, Nasoff M, Nemeth E, Ganz T.

Blood. 2015 Oct 22;126(17):2031-7. doi: 10.1182/blood-2015-07-658419. Epub 2015 Aug 14.

13.

Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Schmidt PJ, Fleming MD.

Hematol Oncol Clin North Am. 2014 Apr;28(2):387-401. doi: 10.1016/j.hoc.2013.11.004. Epub 2014 Jan 18. Review.

14.

Hepcidin in beta-thalassemia.

Nemeth E.

Ann N Y Acad Sci. 2010 Aug;1202:31-5. doi: 10.1111/j.1749-6632.2010.05585.x.

15.

Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.

Gardenghi S, Grady RW, Rivella S.

Hematol Oncol Clin North Am. 2010 Dec;24(6):1089-107. doi: 10.1016/j.hoc.2010.08.003. Epub 2010 Oct 15. Review.

16.

Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.

Ramos P, Melchiori L, Gardenghi S, Van-Roijen N, Grady RW, Ginzburg Y, Rivella S.

Ann N Y Acad Sci. 2010 Aug;1202:24-30. doi: 10.1111/j.1749-6632.2010.05596.x.

17.

Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.

Nai A, Pagani A, Mandelli G, Lidonnici MR, Silvestri L, Ferrari G, Camaschella C.

Blood. 2012 May 24;119(21):5021-9. doi: 10.1182/blood-2012-01-401885. Epub 2012 Apr 6.

18.

β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.

Ginzburg Y, Rivella S.

Blood. 2011 Oct 20;118(16):4321-30. doi: 10.1182/blood-2011-03-283614. Epub 2011 Jul 18. Review.

19.

Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.

Jones E, Pasricha SR, Allen A, Evans P, Fisher CA, Wray K, Premawardhena A, Bandara D, Perera A, Webster C, Sturges P, Olivieri NF, St Pierre T, Armitage AE, Porter JB, Weatherall DJ, Drakesmith H.

Blood. 2015 Jan 29;125(5):873-80. doi: 10.1182/blood-2014-10-606491. Epub 2014 Dec 17.

20.

Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.

Guo S, Casu C, Gardenghi S, Booten S, Aghajan M, Peralta R, Watt A, Freier S, Monia BP, Rivella S.

J Clin Invest. 2013 Apr;123(4):1531-41. doi: 10.1172/JCI66969. Epub 2013 Mar 25.

Supplemental Content

Support Center